Brokerages Set Codexis, Inc. (NASDAQ:CDXS) PT at $7.17

Shares of Codexis, Inc. (NASDAQ:CDXSGet Free Report) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $7.17.

CDXS has been the topic of a number of recent research reports. Piper Sandler cut their target price on Codexis from $14.00 to $10.00 and set an “overweight” rating on the stock in a research note on Monday, November 6th. StockNews.com raised Codexis to a “sell” rating in a research report on Wednesday, January 10th. Finally, Benchmark cut Codexis from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th.

Get Our Latest Stock Report on Codexis

Insider Buying and Selling at Codexis

In other Codexis news, Director Byron L. Dorgan sold 20,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $2.11, for a total value of $42,200.00. Following the transaction, the director now owns 193,461 shares of the company’s stock, valued at $408,202.71. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP bought a new position in shares of Codexis in the first quarter worth about $33,000. Tower Research Capital LLC TRC raised its stake in shares of Codexis by 133.4% in the third quarter. Tower Research Capital LLC TRC now owns 6,007 shares of the biotechnology company’s stock worth $37,000 after buying an additional 3,433 shares during the period. Wells Fargo & Company MN raised its stake in shares of Codexis by 156.6% in the fourth quarter. Wells Fargo & Company MN now owns 6,276 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,830 shares during the period. US Bancorp DE raised its stake in shares of Codexis by 517.5% in the first quarter. US Bancorp DE now owns 8,380 shares of the biotechnology company’s stock worth $172,000 after buying an additional 7,023 shares during the period. Finally, Captrust Financial Advisors bought a new position in shares of Codexis in the second quarter worth about $29,000. Institutional investors own 87.94% of the company’s stock.

Codexis Trading Down 3.1 %

NASDAQ CDXS opened at $2.78 on Monday. Codexis has a 12 month low of $1.45 and a 12 month high of $6.50. The stock has a market cap of $194.04 million, a P/E ratio of -2.32 and a beta of 1.89. The stock’s fifty day moving average price is $2.76 and its 200-day moving average price is $2.28.

About Codexis

(Get Free Report

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Further Reading

Analyst Recommendations for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.